Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Rating) Director Michael Ackermann acquired 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 5th. The shares were bought at an average price of $13.50 per share, for a total transaction of $1,350,000.00. Following the completion of the purchase, the director now owns 100,000 shares in the company, valued at approximately $1,350,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Tarsus Pharmaceuticals stock traded up $0.16 during midday trading on Monday, hitting $11.24. 386,604 shares of the company’s stock were exchanged, compared to its average volume of 90,059. Tarsus Pharmaceuticals, Inc. has a 52-week low of $10.80 and a 52-week high of $39.08. The stock’s 50-day moving average price is $17.57. The firm has a market capitalization of $232.97 million, a P/E ratio of -15.53 and a beta of 1.45.
Tarsus Pharmaceuticals (NASDAQ:TARS – Get Rating) last posted its earnings results on Monday, March 14th. The company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 7.66% and a negative net margin of 24.25%. The business had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $7.11 million. As a group, research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.82 earnings per share for the current year.
A number of analysts recently issued reports on TARS shares. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $55.00 to $66.00 in a research note on Monday, May 2nd. Zacks Investment Research upgraded Tarsus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, February 24th. Finally, HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Tarsus Pharmaceuticals in a research report on Tuesday, May 3rd. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $48.00.
Tarsus Pharmaceuticals Company Profile (Get Rating)
Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
- Get a free copy of the StockNews.com research report on Tarsus Pharmaceuticals (TARS)
- Johnson Outdoors Falls On Bleak Outlook
- Time to Buy These 3 Oversold Mid-Caps
- Institutional Support For Tyson Foods Is Growing
- HCA Healthcare Stock is Ready to Climb Higher
- Littelfuse Stock is Hitting on All Cylinders
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.